Literature DB >> 1722193

Immunotoxin with mistletoe lectin I A-chain and ricin A-chain directed against CD5 antigen of human T-lymphocytes; comparison of efficiency and specificity.

A G Tonevitsky1, U Pfuller, T L Bushueva, G V Ershova, M Gelbin, K Pfuller, I I Agapov, H Franz.   

Abstract

Monoclonal anti-CD5 antibody was coupled to the enzymatically active subunit of plant toxin [either mistletoe lectin I (ML) or ricin]. The obtained conjugates proved to be selectively toxic to CD5-bearing target cells. The immunotoxin prepared from ML A-chain (MLA) was as toxic as native ML and approximately 80-fold more active than the corresponding conjugate with ricin A-chain (RTA). The comparative studies of the structural properties of isolated MLA and RTA were carried out using intrinsic fluorescence spectroscopy. The results showed similar properties for both proteins. No antigenic cross-reactivity against both toxins was detected when using polyclonal antibodies. The results suggest that MLA-antibody conjugates may be potential candidates for therapeutical use.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722193     DOI: 10.1016/0192-0561(91)90059-g

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  3 in total

Review 1.  A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics.

Authors:  Haike Ghazarian; Brian Idoni; Steven B Oppenheimer
Journal:  Acta Histochem       Date:  2010-03-02       Impact factor: 2.479

2.  Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines.

Authors:  U Schumacher; A Stamouli; E Adam; M Peddie; U Pfüller
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

Review 3.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.